In this way, the autoregulatory loop between HIF-1 and HIPK2 modifies the downstream pathways regulated by both proteins, and its balance may dictate the cancer survival/cell death outcome in response to therapies [71,72] (Figure 2). The gene discussed is HIF1A; the disease is cancer.